Main Menu

Autologous Granulocyte Therapy, a cutting-edge advancement in the treatment of Chronic Granulomatous Disease (CGD), offers a groundbreaking solution to the challenges faced by CGD patients. This innovative technology involves correcting the genetic defects in the patient's own phagocytes by providing the missing messenger RNA (mRNA) required for protein production. These functionally corrected autologous granulocytes can then be reintroduced into the patient's system to combat severe infections.

This technology involves the development of live attenuated vaccine candidates for respiratory syncytial virus (RSV), a significant cause of severe respiratory tract diseases, particularly in infants and young children. The approach focuses on relocating the NS1 and NS2 genes within the RSV genome to downstream positions, resulting in reduced transcription and expression. This gene-shifting strategy allows for controlled attenuation of the virus, avoiding over-attenuation seen with gene deletion. Combining gene shifts with other mutations fine-tunes the level of attenuation.

Cutting-edge research has led to the development of highly potent monoclonal antibodies (mAbs) targeting the circumsporozoite protein (CSP) in the fight against malaria. These fully human recombinant mAbs, isolated from immunized volunteers, exhibit exceptional blocking capacity, with a potency 100 times greater than existing mouse monoclonal CSP antibodies. This breakthrough paves the way for a novel strategy in malaria prevention, offering hope to millions of individuals worldwide, including travelers, military personnel, diplomats, and those residing in malaria-endemic regions.

The developed technology is a high-affinity polyclonal antibody targeting BST-2, a crucial surface antigen involved in restricting the replication of HIV-1 and other enveloped viruses. This antibody, generated from recombinant BST-2 ectodomain protein, offers versatility in various research techniques, such as FACS, immunoblotting, immunofluorescence, and immunoprecipitation. Additionally, it exhibits bioactivity, effectively inhibiting BST-2 function in virus-producing cells.

This technology introduces a groundbreaking method for discovering and isolating anti-idiotypic antibodies, with a primary focus on inhibiting or extinguishing the activity of VRCOl, a broadly neutralizing anti-HIV-1 antibody. These anti-idiotypic antibodies provide a vital mechanism for controlling adverse events that may result from therapeutic antibody administration. The innovative method involves immunizing animals with specific antibody fragments, followed by systematic selection and isolation of somatically mutated B cells.

This technology presents a sophisticated two-step vaccination approach designed to provide comprehensive protection against filovirus infections, including Ebola and Marburg viruses. It involves administering a prime-boost vaccine sequence, employing replication-defective adenoviral serotype 26 (Ad26) as the priming agent and replication-defective adenoviral serotype 35 (Ad35) as the boosting agent. Both vectors are engineered to express the crucial filovirus envelope glycoprotein (GP), encompassing various strains of Ebolavirus (EBOV) and Marburg (MAR).

This groundbreaking technology introduces a highly potent, human anti-HIV antibody that targets a novel epitope, surpassing the efficacy of existing anti-HIV antibodies. With a prolonged half-life, it offers versatile applications, including early-stage HIV treatment, newborn prophylaxis, and vaccine development validation. Collaborative efforts aim to harness its potential for antibody-dependent cell-mediated cytotoxicity (ADCC) against HIV-infected cells.

The technology involves the development of monoclonal antibodies produced by hybridomas, including cell lines such as 10G3, 3E6, 10D4, 10G4, 1D8, 13D10, 9E5, and 9F10, which specifically react with Bacillus anthracis Lethal Factor (LF). These monoclonal antibodies offer valuable applications in anthrax detection, therapeutic intervention, and research into the biology of Bacillus anthracis and its lethal toxin. This advancement provides promising tools for mitigating the impact of anthrax infections and advancing our understanding of this deadly pathogen.

This technology includes a large panel of monoclonal antibodies (mAbs) against the spike glycoprotein, capable of recognizing intact SARS-CoV-2 virions with high affinity. Data to support SARS-CoV-2-specific binding include ELISA and label-free (biolayer interferometry) binding measurements using recombinant proteins, immunofluorescence in culture, immunofluorescence staining of tissue from infected patients, and virus neutralization assays.

This technology includes human F(ab’)2 fragments specific for anthrax lethal factor for the development of a lateral flow immunoassay for Bacillus anthracis Lethal Factor. The F(ab’)2 fragments are generated from a Human Combinatorial Antibody Library (HuCAL) and are highly specific with high affinity. A multi-step process was utilized beginning by screening a phage display library with over 45 billion functional human antibody specificities. The primary screen against Bacillus anthracis Lethal Factor (LF) generated 360 positive clones.